Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 3Phase 1 3Phase NA 2Phase 4 2Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 134Neoplasms 112Polycystic Ovary Syndrome 66Prostatic Neoplasms 63Colorectal Neoplasms 51Carcinoma, Non-Small-Cell Lung 47Pain 40Carcinoma, Hepatocellular 35Lung Neoplasms 34Keratosis, Actinic 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Neoplasm Metastasis 26Head and Neck Neoplasms 26Pain, Postoperative 25Stomach Neoplasms 24Colonic Neoplasms 23Multiple Myeloma 22Brain Neoplasms 21Pancreatic Neoplasms 20Lymphoma, Follicular 19Leukemia 19Anemia 19Uterine Cervical Neoplasms 18Leukemia, Myeloid, Acute 18Infertility 18Leiomyoma 17Lymphoma, Non-Hodgkin 16Lymphoma 16Cancer Pain 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15

Interventions

Everolimus 1Doxycycline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Completed × Lymphangioleiomyomatosis × Clear all
NCT03525834 2021-09-09

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Novartis

Phase 4 Completed
40 enrolled 10 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

NCT00989742 2015-12-02

Doxycycline In Lymphangioleiomyomatosis (LAM)

University of Nottingham

Phase 4 Completed
24 enrolled

Tuberous Sclerosis, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡